About

Mission

Facilities

Collaboration Partners

Technology

T-cell therapy

REVITA technology

Benefits

IP

Clinical

Pipeline

Publications

Team

Management

Board of Directors

Scientific advisors

Career

Why Cbio

Job Openings

Contact

info@cbio.dk

+45 30 40 99 73

Cbio A/S
Transformervej 8
Dk-2860 Søborg
Denmark

CVR-no. 40216642

<
>

Strong promise for Cbio's T-cell therapy product

Pipeline

Publications

Clinical

Strong Pipeline Targeting 4 Cancer Indications With High Unmet Medical Need (Ny tekst her)

Pipeline

Cbio’s is working with Karolinska in Stockholm in preparing for a clinical phase I/II study in cervical cancer.

In addition, Cbio is collaborating with Odense University Hospital in Denmark, to evaluate the feasibility and develop novoleucel for an additional four cancer indications: colorectal, ovarian, kidney, and pancreatic cancer.

Novoleucel next generation manufacturing protocol (Cbio proprietary)

novoleucel clinical pipeline

T-cell product: CB-105

Pre-clinical study with Odense University Hospital

TIL product: CB-105

Publications/key references

<
>
2022

Neo-antigen reactive T-cells affect clinical outcome in TIL therapy in melanoma

A broader T-cell repertoire is a great predicter for improved clinical outcome in TIL therapy in melanoma. Christina Heeke from our R&D team is co-first-author on this very interesting article investigating what exact epitopes that TIL therapy is actually reacting against.

A broader T-cell repertoire is a great predicter for improved clinical outcome in TIL therapy in melanoma. Christina Heeke from our R&D team is co-first-author on this very interesting article investigating what exact epitopes that TIL therapy is actually reacting against.

Read Publication
2020

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ Tumor Infiltrating Lymphocytes in ovarian cancer, Friese, C. et al, Nature SR (2020)

Article investigating the effect of adding a αCTLA-4 during the initial TIL culture, which favors the expansion of CD8+ TILs from ovarian tumor fragments. Adding αCTLA-4 resulted in more potent anti-tumor TILs in comparison to standard TIL cultures, which may improve clinical outcome of TIL-based ACT in ovarian cancer.

Article investigating the effect of adding a αCTLA-4 during the initial TIL culture, which favors the expansion of CD8+ TILs from ovarian tumor fragments. Adding αCTLA-4 resulted in more potent anti-tumor TILs in comparison to standard TIL cultures, which may improve clinical outcome of TIL-based ACT in ovarian cancer.

Read Publication
2021

High-dose Tumor Infiltrating Lymphocyte product with improved phenotype and functionality, Friese, C et al. SITC 2021 conference (abstract # 175)

Poster illustrating that improving the initial TIL culture conditions results in a shortened expansion time while simultaneously improving the characteristics of the TIL product with a high dose of functional CD8+ T cells with potential anti-tumor activity

Poster illustrating that improving the initial TIL culture conditions results in a shortened expansion time while simultaneously improving the characteristics of the TIL product with a high dose of functional CD8+ T cells with potential anti-tumor activity

Read Publication

We use cookies to enhance the experience of this site

Read about cookie policy
Accept cookies